Phacilitate Leaders World


John  Beadle

John Beadle

CEO, PsiOxus
Dr Beadle is the Chief Executive Officer of Psioxus Therapeutics Ltd., a private company developing immuno-oncology therapeutics and headquartered in Oxford, UK with offices near Philadelphia, USA. PsiOxus is focused upon developing oncolytic viruses for the treatment of solid tumors utilising the proprietary Tumor Specific Immuno Gene Therapy (T-SiGn) platform. The company has two clinical stage collaborations with BMS and an extensive pre-clinical follow-on pipeline. John was previously Co-founder and Chief Medical Officer of PowderMed Ltd., a private Oxford, UK biotech company, which he helped to build and lead before a successful trade sale in 2007 to Pfizer. He then became Entrepreneur in Residence at Imperial College London and has held the role of CEO in a number of start-up and early stage biotech companies. He was CEO of both Myotec Therapeutics and Hybrid Biosytems, before merging the two companies in 2011 to form PsiOxus Therapeutics.


In his early career, John held Research and Development roles of ascending seniority within The Wellcome Foundation, GlaxoWellcome and GlaxoSmithkline, where he was most recently the Vice President of Global Medical Operations. He was then Vice President of Product Development at the vaccines company PowderJect. John graduated as a Medical Doctor from the University of Witwatersrand and received his Masters of Business Administration from the London Business School.
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman